1. bookVolume 60 (2010): Issue 1 (March 2010)
Journal Details
License
Format
Journal
eISSN
1846-9558
ISSN
1330-0075
First Published
28 Feb 2007
Publication timeframe
4 times per year
Languages
English
Open Access

RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditions

Published Online: 13 Mar 2010
Volume & Issue: Volume 60 (2010) - Issue 1 (March 2010)
Page range: 13 - 24
Journal Details
License
Format
Journal
eISSN
1846-9558
ISSN
1330-0075
First Published
28 Feb 2007
Publication timeframe
4 times per year
Languages
English
RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditions

A simple, sensitive and precise RP-HPLC-DAD method was developed and validated for the determination of olmesartan medoxomil (AT-II receptor blocker) in the presence of its degradation products. Olmesartan medoxomil and all the degradation products were resolved on a C18 column with the mobile phase composed of methanol, acetonitrile and water (60:15:25, V/V/V, pH 3.5 by orthophosphoric acid) at 260 nm using a photodiode array detector. The method was linear over the concentration range of 1-18 μg mL-1 and precise with RSD < 1 % in intra- and inter-day study. Excellent recoveries of 99.3 ± 0.9 to 100.8 ± 1.2% proved the accuracy of the method. Developed method was specific, as indicated by chromatographic resolution > 2.0 for each peak and sensitive with LOD 0.03 μg mL-1 and LOQ 0.1 μg mL-1. The method was used to study the drug degradation behavior under forced conditions. Four degradation products (DP-I, II, III, IV) were formed during the degradation study in 0.1 mol L-1 HCl whereas only DP-I, II and III were formed in water, 0.01 mol L-1 NaOH and 3% H2O2. No significant thermal or photolytic degradation was observed in solid drug. The method was applied successfully for the assay of olmesartan medoxomil in the tablet dosage form.

Keywords

FDA, Draft Guidance for Industry: Stability Testing of Drug Substances and Drug Products, FDA, Rockville 1998.Search in Google Scholar

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A (R2), Step 5, ICH Geneva, Aug. 2003.Search in Google Scholar

H.R. Brunner, The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview, J. Hum. Hypertens. 16 (2002) S13-S16; DOI: 10.1038/sj/jhh/1001391.Search in Google Scholar

H. Koike, T. Konse, T. Sada, T. Ikeda, S. Hyogo, D. Hinman, H. Saito, and H. Yanagisawa, Olmesartan medoxomil, a novel potent angiotensin II blocker, Ann. Rep. Snakyo Res. Lab. 55 (2003) 1-91.Search in Google Scholar

D.E. Mire, T.N. Silfani and M.K. Pugsley, A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker, J. Cardiovasc. Pharmacol. 46 (2005) 585-593; DOI: 10.1097/01.fjc.0000180902.78230.fd.10.1097/01.fjc.0000180902.78230.fd16220064Search in Google Scholar

H. Koike, T. Sada and M. Mizuno, In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist, J. Hypertens. 19 (Suppl) (2001) S3-S14.10.1097/00004872-200106001-0000211451212Search in Google Scholar

G.T. Warner and B. Jarvis, Olmesartan medoxomil, Drugs 62 (2002) 1345-1353.10.2165/00003495-200262090-0000512076183Search in Google Scholar

O. Sagirli, A. Önal, S.E. Toker and D. Sensoy, Simultaneous HPLC analysis of olmesartan and hydrochlorothiazide in combined tablets and in vitro dissolution studies, Chromatographia 66 (2007) 213-218; DOI: 10.1365/s10337-007-0304-9.10.1365/s10337-007-0304-9Search in Google Scholar

K. Yoshihara, Y. Gao, H. Shiga, D.R. Wada and M. Hisaoka, Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients, Clin. Pharmacokin., 44 (2005) 1329-1342.Search in Google Scholar

H. Nakamura, T. Inoue, N. Arakawa, Y. Shimizu, Y. Yoshigae, I. Fujimori, E.H. Nakamura, T. Inoue, N. Arakawa, Y. Shimizu, Y. Yoshigae, I. Fujimori, E. Shimakawa, T. Toyoshi and T. Yokoyama, Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models, Eur. J. Pharmacol. 512 (2005) 239-246; DOI: 10.1016/j.ejphar.2005.02.047.10.1016/j.ejphar.2005.02.04715840410Search in Google Scholar

V.V. Vaidya, S.M. Roy, S.M. Yetal, S.S. Joshi and S.A. Parekh, LC-MS-MS determination of olmesartan in human plasma, Chromatographia 67 (2008) 147-150; DOI: 10.1365/s10337-007-0453-x.10.1365/s10337-007-0453-xSearch in Google Scholar

L. Dongyang, H. Pei, M. Nobuka, L. Xiaoming, L. Li and J. Ji, Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry, J. Chromatogr. B 856 (2007) 190-197; DOI: 10.1016/j.jchromb.2007.05.049.10.1016/j.jchromb.2007.05.04917602900Search in Google Scholar

N.J. Shah, B.N. Suhagia, R.R. Shah and N.M. Patel, Development and validation of a simultaneous HPTLC method for the estimation of olmesartan medoxomil and hydrochlorothiazide in tablet dosage form, Indian J. Pharm. Sci. 69 (2007) 834-836; DOI: 10.4103/0250-474X.39447.10.4103/0250-474X.39447Search in Google Scholar

C. Mustafa and A. Sacide, Development of a CZE method for the determination of olmesartan medoxomil in tablets, Chromatographia 66 (2007) 929-933; DOI: 10.1365/s10337-007-0424-2.10.1365/s10337-007-0424-2Search in Google Scholar

T. Murakami, H. Konno, N. Fukutsu, M. Onodera, T. Kawasaki and F. Kusu, Identification of a degradation product in stressed tablets of olmesartan medoxomil by the complementary use of HPLC hyphenated techniques, J. Pharm. Biomed. Anal. 47 (2008) 553-559; DOI: 10.1016/j.jpba.2008.02.021.10.1016/j.jpba.2008.02.02118394840Search in Google Scholar

International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guidelines, Validation of Analytical Procedure: Text and Methodology Q2 (R1), Current Step 4 version, ICH Geneva, Nov. 2005.Search in Google Scholar

G.W. Ewing, Instrumental Methods of Chemical Analysis, 5th ed., Lippincott-Raven, Philadelphia 1995, pp. 484-486.Search in Google Scholar

Z. Zhao, Q. Wang, E.W. Tsai, X.Z. Qin and D. Ip, Identification of losartan degradates in stressed tablets by LC-MS and LC-MS/MS, J. Pharm. Biomed. Anal. 20 (1999) 129-36; DOI: 10.1016/S0731-7085(99)00004-7.10.1016/S0731-7085(99)00004-7Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo